Alert (RVNC): Have you lost money on your Revance Therapeutics investment? Contact Johnson Fistel about the investigation
SAN DIEGO, October 30, 2021 (GLOBE NEWSWIRE) – Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Revance Therapeutics, Inc. (“Revance” or “The Company”) (NASDAQ: RVNC).
On October 15, 2021, Revance revealed that the FDA could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its current form, citing shortcomings related to an inspection of Revance’s manufacturing plant. The report comes after the company said late on October 12, after Revance shares plunged 25.1% that day, that it continued to expect the FDA to approve DaxibotulinumtoxinA for injection this day. year.
If you have any information that could assist with this investigation, including former employees and others, or a Revance shareholder and would like to learn more about the investigation, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If you are sending an email, please include a phone number.
In addition, you can [click here to join this action]. There is no cost or obligation for you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in class actions between shareholders and derivatives. For more information on the firm and its lawyers, visit http://www.johnsonfistel.com. Lawyer advertising. Past results do not guarantee future results.
Johnson Fistel, srl
Jim Baker, 619-814-4471